How Maxion’s KnotBody® Platform Is Changing the Way We Treat the ‘Undruggable’

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/9f/46/ef/9f46efb8-6561-a846-7ca8-f8a3628a99dd/mza_5157767897053810333.jpeg/600x600bb.jpg

Leading Beyond The Lab

ARTO Talent

20 episodes

1 month ago

The Leading Beyond The Lab Podcast is hosted by Lawrence Rose, one of the Directors at ARTO, a talent solutions agency specialising in leadership roles within the Life Sciences sector globally.

This podcast provides insightful discussions with industry experts, leaders and innovators, shaping the future in drug development and clinical devices. We talk with biotechnology and/or pharmaceutical executives, and find out from them their stories, personal career development and analyse their opinion on how to become successful in this space. We talk on a range of topics including soft skills, oncology, leadership, micromanagement, investment, cardiology, AI, dementia, addiction, hematology, dermatology, and much more.

This podcast applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.

Hosted on Acast. See acast.com/privacy for more information.

All content for Leading Beyond The Lab is the property of ARTO Talent and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

This podcast applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.

Hosted on Acast. See acast.com/privacy for more information.

How Maxion’s KnotBody® Platform Is Changing the Way We Treat the ‘Undruggable’

Leading Beyond The Lab

32 minutes 42 seconds

2 months ago

How Maxion’s KnotBody® Platform Is Changing the Way We Treat the ‘Undruggable’

Dr. Arndt Schottelius, CEO of Maxion Therapeutics, is a physician-scientist with a standout career across Genentech, MorphoSys, Kymab, and now at one of the UK’s most promising biotech companies. At Maxion, he leads a team pioneering KnotBody technology - an innovative approach to targeting ion channels and GPCRs, long considered “undruggable” with biologics. Arndt brings more than 25 years of experience across translational science, drug development and leadership in global R&D. His conviction, clarity, and track record - including developing molecules that have become partnered, acquired and approved - makes this conversation a must-listen for anyone in life sciences leadership.

In this episode, we cover:

How Maxion is building a new therapeutic modality using KnotBody technology to tackle autoimmune and inflammatory diseases
Why conviction, speed, and storytelling are non-negotiable in translational drug development
Lessons from Genentech, MorphoSys, and Kymab on building pipelines, teams, and partnerships
What investors really look for - and how Maxion secured a competitive Series A in a tough market
How to hire and scale for scientific excellence without losing agility or collaboration

Tune in for a dynamic, insightful conversation with one of biotech’s most experienced and thoughtful leaders.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Arndt Schottelius

CEO at Maxion Theraprutics

LinkedIn: https://www.linkedin.com/in/arndt-schottelius-md-ph/